Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Infliximab for Crohn's Disease: More Than 13 Years of Real-world Experience.
Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Safdi M, Popp JW Jr, Langholff W, Sandborn WJ. Lichtenstein GR, et al. Among authors: safdi m. Inflamm Bowel Dis. 2018 Feb 15;24(3):490-501. doi: 10.1093/ibd/izx072. Inflamm Bowel Dis. 2018. PMID: 29462395 Free PMC article.
Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report.
Lichtenstein GR, Feagan BG, Mahadevan U, Salzberg BA, Langholff W, Morgan JG, Safdi M, Nissinen R, Taillard F, Sandborn WJ, Cohen RD. Lichtenstein GR, et al. Among authors: safdi m. Am J Gastroenterol. 2018 Nov;113(11):1678-1688. doi: 10.1038/s41395-018-0202-9. Epub 2018 Jul 19. Am J Gastroenterol. 2018. PMID: 30022113
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.
Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, Patel K, Wolf DC, Safdi M, Colombel JF, Lashner B, Hanauer SB. Rutgeerts P, et al. Among authors: safdi m. Gastrointest Endosc. 2006 Mar;63(3):433-42; quiz 464. doi: 10.1016/j.gie.2005.08.011. Gastrointest Endosc. 2006. PMID: 16500392 Clinical Trial.
Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies.
Sandborn WJ, Hanauer S, Lichtenstein GR, Safdi M, Edeline M, Scott Harris M. Sandborn WJ, et al. Among authors: safdi m. Aliment Pharmacol Ther. 2011 Oct;34(7):747-56. doi: 10.1111/j.1365-2036.2011.04800.x. Epub 2011 Aug 16. Aliment Pharmacol Ther. 2011. PMID: 21848857 Free article.
5-ASA Dose-Response: Maximizing Efficacy and Adherence.
Katz S, Lichtenstein GR, Safdi MA. Katz S, et al. Among authors: safdi ma. Gastroenterol Hepatol (N Y). 2010 Feb;6(2 Suppl 3):1-16. Gastroenterol Hepatol (N Y). 2010. PMID: 20567558 Free PMC article.
Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis.
Sandborn WJ, Korzenik J, Lashner B, Leighton JA, Mahadevan U, Marion JF, Safdi M, Sninsky CA, Patel RM, Friedenberg KA, Dunnmon P, Ramsey D, Kane S. Sandborn WJ, et al. Among authors: safdi m. Gastroenterology. 2010 Apr;138(4):1286-96, 1296.e1-3. doi: 10.1053/j.gastro.2009.12.054. Epub 2010 Jan 11. Gastroenterology. 2010. PMID: 20064514 Clinical Trial.
44 results